Adriamycin induced G2/M cell cycle arrest in transitional cell cancer cells with wt p53 and p21WAF1/CIP1 genes

Journal of Experimental and Clinical Cancer Research

Volumn 19, Issue 4, 2000, Pages 483-488

  Bilim, V ^a   Kawasaki, T ^a   Takahashi, K ^a   Tomita, Y ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Adriamycin; Cell cycle; Cyclin dependent kinases; Cyclins; Retinoblastoma protein; Transitional cell cancer

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; DOXORUBICIN; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOXORUBICIN; ENZYME INHIBITORS; FLOW CYTOMETRY; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; KINETICS; MITOSIS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0034463604     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. G1 phase progression: Cyclines on cue
2. The retinoblastorna protein is phosphorylated during specific phases of the cell cycle
3. Evidence that the G1-S and G2-M transitions are controlled by different cdc 2 proteins in higher eukaryotes
4. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner
5. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
6. WAF 1, a potential mediator of p53 tumor suppression
7. p21 is a universal inhibitor of cyclin kinases
8. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
9. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
10. p21 is necessary for the p53-mediated G1 arrest in human cancer cells
11. Resistance of MCF7 human carcinoma cells to TNF-induced cell death is associated with loss of p53 function
12. Flavonoids activate wild-type p53
13. p53 controls both the G2/M and G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts
14. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio
15. The anthracycline antineoplastic drugs
16. mRNA and protein expression of p53 mutations in human bladder cancer cell lines
17. WAF1/CIP1 and/or p53 gene alterations
18. WAF1/CIP1 induction
19. Radiation-induced cell cycle arrest compromised by p 21 deficiency
20. WAF1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells
21. Control of G1 progression by D-type cyclins: Key event for cell proliferation
22. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
23. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation
24. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression
25. Transcriptional regulation. A closer look at E2F
26. The inter-actions of E2F with pRB and with p107 are regulated via the phosphorylation of pRB and p107 by a cyclin-dependent kinase
27. Essential role of E 2F recognition sites in regulation of the proliferating cell nuclear antigen gene promoter during Drosophila development
28. Ultraviolet B irradiation-induced G 2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase
29. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21
30. p53 is required for radiation-induced apoptosis in mouse thymocytes
31. p21-dependent apoptosis modulates the cytotoxicity of anticancer agents